The Benefits of Iodine and Selenium in treating Fibrocystic Breast Disease - OAWHealth

The Benefits of Iodine and Selenium in treating Fibrocystic Breast Disease

The Benefits of Iodine and Selenium in treating Fi...

The Benefits of Iodine and Selenium in Treating Fibrocystic Breast Disease

 

FIBROCYSTIC BREAST DISEASE

Blood levels of selenium are lower in females with Fibrocystic Breast Disease than in normals.

Jpn J Cancer Res 1985 May;76(5):374-7

 


Selenium in the blood of Japanese and American women with and without breast cancer and fibrocystic disease.

Schrauzer GN, Molenaar T, Mead S, Kuehn K, Yamamoto H, Araki E

Selenium concentrations in whole blood of Japanese and American women with and without breast cancer and benign fibrocystic breast disease were determined. The observed blood Se levels of healthy Japanese women (0.286 +/- 0.021 micrograms/ml) were similar to previously reported values for healthy Japanese adults. The Japanese patients with benign breast disease and with breast cancer exhibited blood selenium concentrations of 0.200 +/- 0.045 and 0.195 +/- 0.057 micrograms/ml, respectively. The mean blood Se concentration of Japanese breast cancer patients with recurrence was 0.188 +/- 0.061 micrograms/ml. The mean blood Se concentrations of healthy American women from San Diego, Calif., were 0.191 +/- 0.023 micrograms/ml; of women with benign fibrocystic disease, 0.142 +/- 0.010 micrograms/ml; and of breast cancer patients, 0.167 +/- 0.032 micrograms/ml. The higher blood Se concentrations of Japanese healthy subjects as compared to healthy Americans can be attributed to differences in the dietary Se intakes; low blood Se concentration may be indicative of increased breast cancer risk.

The following study shows the benefits of iodine to fibrocystic breast disease. This study appears to indicate that iodine deficiency is involved in the etiology of fibrocystic breast disease.

Can J Surg 1993 Oct;36(5):453-60

 


Iodine replacement in fibrocystic disease of the breast.

Ghent WR, Eskin BA, Low DA, Hill LP

Department of Surgery, Queen's University, Hotel Dieu Hospital, Kingston, Ont.

OBJECTIVE: To determine the response of patients with fibrocystic breast disease to iodine replacement therapy. DESIGN: Review of three clinical studies beginning in 1975: an uncontrolled study with sodium iodide and protein-bound iodide; a prospective, control, crossover study from iodide to molecular iodine; and a prospective, control, double-blind study with molecular iodine. SETTING: University affiliated breast-treatment clinics. PATIENTS: Study 1: 233 volunteers received sodium iodide for 2 years and 588 received protein-bound iodide for 5 years. Study 2: the treatment of 145 patients from study 1 treated with protein-bound iodide for several months who still had symptoms was switched to molecular iodine 0.08 mg/kg; 108 volunteers were treated initially with molecular iodine. Study 3: 23 patients received molecular iodine, 0.07 to 0.09 mg/kg body weight; 33 received an aqueous mixture of brown vegetable dye and quinine. The numbers in study 2 increased over the review period so that 1365 volunteers were being treated with molecular iodine by 1989. INTERVENTIONS: All patients in study 3 had pre- and post-treatment mammography and measurement of serum triiodothyronine, thyroxine and thyroid-stimulating hormone levels. MAIN OUTCOME MEASURES: Subjective evaluation–freedom from pain–and objective evaluation–resolution of fibrosis. RESULTS: Study 1: 70% of subjects treated with sodium iodide had clinical improvement in their breast disease, but the rate of side effects was high; 40% of patients treated with protein-bound iodide had clinical improvement. Study 2: 74% of patients in the crossover series had clinical improvement, and objective improvement was noted in 72% of those who received molecular iodine initially. Study 3: in the treatment group 65% had subjective and objective improvement; in the control group there was a subjective placebo effect in 33% and an objective deterioration of 3%. CONCLUSIONS: The fibrocystic breast reacts differently to sodium iodide, protein-bound iodide and molecular iodine. Molecular iodine is nonthyrotropic and was the most beneficial.

Arch Pathol Lab Med 1979 Nov;103(12):631-4

 


Age-related changes resembling fibrocystic disease in iodine-blocked rat breasts.

Krouse TB, Eskin BA, Mobini J

It has been reported that dietary restriction and chemical blockade of iodine causes histopathologic changes in peripubertal female rat breasts. This study extended the age range to include midreproductive life and perimenopausal rats; there is a wider spectrum of structural alterations that are associated with the older breast, with sodium perchlorate as the blocking agent. In 16-week-old rats, breasts showed general increased parenchymal activity and growth, regressing after removal of the block. In 42-week-old rats, breasts showed noticeable calcospherite deposition, intralobular fibrosis, and cystic changes resembling human fibrocystic disease. In 52-week-old rats, breasts exhibited atypical lobules cytologically, papillomatosis, sclerosing adenosis, calcifications, and a lobular transformation of a histologically dysplastic type. It is the older rat that experiments will more closely parallel the human condition.

Join Thousands of People & Receive - Advanced Health & Wellness Monthly Newsletter
x
Join Our Wellness Newsletter!